The European Commission announced on Friday 22 October that it had established a “portfolio” of ten therapeutic treatments for Covid-19(see EUROPE B12752A16).
Six of the treatments in the Commission’s sights are already under rolling review or have already been submitted to the European Medicines Agency (EMA) for marketing authorisation.
The other four candidates on the Commission’s list have all received scientific opinions from the EMA and, once sufficient clinical data has been...